tiprankstipranks
Hansa Biopharma AB (SE:HNSA)
:HNSA
Sweden Market
HNSA
Hansa Biopharma AB
RESEARCH TOOLSreports

Hansa Biopharma AB (HNSA) Stock Forecast & Price Target

16 Followers
See the Price Targets and Ratings of:

HNSA Analyst Ratings

Moderate Buy
1Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Hansa
Biopharma AB
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HNSA Stock 12 Month Forecast

Average Price Target

kr103.00
▲(235.29% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Hansa Biopharma AB in the last 3 months. The average price target is kr103.00 with a high forecast of kr103.00 and a low forecast of kr103.00. The average price target represents a 235.29% change from the last price of kr30.72.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"kr21","104":"kr104","41.75":"kr41.8","62.5":"kr62.5","83.25":"kr83.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr103.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr103.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr103.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,41.75,62.5,83.25,104],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,38.38461538461539,43.769230769230774,49.15384615384615,54.53846153846154,59.92307692307693,65.3076923076923,70.6923076923077,76.07692307692308,81.46153846153847,86.84615384615385,92.23076923076923,97.61538461538461,{"y":103,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,38.38461538461539,43.769230769230774,49.15384615384615,54.53846153846154,59.92307692307693,65.3076923076923,70.6923076923077,76.07692307692308,81.46153846153847,86.84615384615385,92.23076923076923,97.61538461538461,{"y":103,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,38.38461538461539,43.769230769230774,49.15384615384615,54.53846153846154,59.92307692307693,65.3076923076923,70.6923076923077,76.07692307692308,81.46153846153847,86.84615384615385,92.23076923076923,97.61538461538461,{"y":103,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.74,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.26,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":32,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 73, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":33,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 64, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Targetkr103.00Average Price Targetkr103.00Lowest Price Targetkr103.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on SE:HNSA
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
kr103
Buy
235.29%
Upside
Reiterated
03/06/26
Imlifidase: Extended FDA Review Seen as Timing-Driven, Not Risk-Driven, Supporting Buy Rating on Strong Unmet-Need and Efficacy Profile
Wedbush Analyst forecast on SE:HNSA
David Nierengarten
Wedbush
Wedbush
kr69
Buy
124.61%
Upside
Initiated
01/07/26
Hansa Biopharma initiated with an Outperform at WedbushHansa Biopharma initiated with an Outperform at Wedbush
Leerink Partners Analyst forecast on SE:HNSA
Thomas Smith
Leerink Partners
Leerink Partners
kr102
Buy
232.03%
Upside
Initiated
11/26/25
Hansa Biopharma's Growth Potential: Buy Rating Backed by Promising Idefirix Trials and Expanding Pipeline
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on SE:HNSA
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
kr103
Buy
235.29%
Upside
Reiterated
03/06/26
Imlifidase: Extended FDA Review Seen as Timing-Driven, Not Risk-Driven, Supporting Buy Rating on Strong Unmet-Need and Efficacy Profile
Wedbush Analyst forecast on SE:HNSA
David Nierengarten
Wedbush
Wedbush
kr69
Buy
124.61%
Upside
Initiated
01/07/26
Hansa Biopharma initiated with an Outperform at WedbushHansa Biopharma initiated with an Outperform at Wedbush
Leerink Partners Analyst forecast on SE:HNSA
Thomas Smith
Leerink Partners
Leerink Partners
kr102
Buy
232.03%
Upside
Initiated
11/26/25
Hansa Biopharma's Growth Potential: Buy Rating Backed by Promising Idefirix Trials and Expanding Pipeline
Stocks with the Highest Top Analyst Consensus in the General Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hansa Biopharma AB

3 Months
xxx
Success Rate
8/22 ratings generated profit
36%
Average Return
+0.44%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 36.36% of your transactions generating a profit, with an average return of +0.44% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
8/22 ratings generated profit
36%
Average Return
-4.39%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -4.39% per trade.
2 Years
xxx
Success Rate
8/22 ratings generated profit
36%
Average Return
-6.84%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of -6.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HNSA Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
5
5
4
4
3
Buy
0
0
0
0
0
Hold
17
20
25
73
64
Sell
1
4
4
4
1
Strong Sell
0
0
0
0
0
total
23
29
33
81
68
In the current month, HNSA has received 3 Buy Ratings, 64 Hold Ratings, and 1 Sell Ratings. HNSA average Analyst price target in the past 3 months is 103.00.
Each month's total comprises the sum of three months' worth of ratings.

HNSA Financial Forecast

HNSA Earnings Forecast

Next quarter’s earnings estimate for HNSA is -kr1.45 with a range of -kr1.68 to -kr1.31. The previous quarter’s EPS was -kr1.62. HNSA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.89% of the time in the same period. In the last calendar year HNSA has Performed in-line its overall industry.
Next quarter’s earnings estimate for HNSA is -kr1.45 with a range of -kr1.68 to -kr1.31. The previous quarter’s EPS was -kr1.62. HNSA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.89% of the time in the same period. In the last calendar year HNSA has Performed in-line its overall industry.

HNSA Sales Forecast

Next quarter’s sales forecast for HNSA is kr48.31M with a range of kr43.50M to kr56.30M. The previous quarter’s sales results were kr75.99M. HNSA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 53.24% of the time in the same period. In the last calendar year HNSA has Performed in-line its overall industry.
Next quarter’s sales forecast for HNSA is kr48.31M with a range of kr43.50M to kr56.30M. The previous quarter’s sales results were kr75.99M. HNSA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 53.24% of the time in the same period. In the last calendar year HNSA has Performed in-line its overall industry.

HNSA Stock Forecast FAQ

What is SE:HNSA’s average 12-month price target, according to analysts?
Based on analyst ratings, Hansa Biopharma AB’s 12-month average price target is 103.00.
    What is SE:HNSA’s upside potential, based on the analysts’ average price target?
    Hansa Biopharma AB has 235.29% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Hansa Biopharma AB a Buy, Sell or Hold?
          Hansa Biopharma AB has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Hansa Biopharma AB’s share price target?
            The average share price target for Hansa Biopharma AB is 103.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is kr103.00 ,and the lowest forecast is kr103.00. The average share price target represents 235.29% Increase from the current price of kr30.72.
              What do analysts say about Hansa Biopharma AB?
              Hansa Biopharma AB’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Hansa Biopharma AB?
                To buy shares of SE:HNSA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.